NewAmsterdam Pharma Company N.V. (NAMS) – What Are Brokerages Thinking About This Stock?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $49.00.

NAMS has been the subject of a number of research analyst reports. Royal Bank Of Canada lowered their price target on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, July 20th.

NewAmsterdam Pharma Stock Down 5.0%

NASDAQ NAMS opened at $20.19 on Wednesday. NewAmsterdam Pharma has a 52 week low of $20.04 and a 52 week high of $42.21. The stock has a market capitalization of $2.41 billion, a PE ratio of -9.35 and a beta of 0.10. The firm has a 50 day moving average of $24.64 and a two-hundred day moving average of $29.82.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $2.83 million. On average, equities research analysts expect that NewAmsterdam Pharma will post -1.82 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, insider Johannes Kastelein sold 50,246 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total value of $1,257,657.38. Following the completion of the sale, the insider directly owned 69,302 shares of the company’s stock, valued at $1,734,629.06. This represents a 42.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Davidson purchased 10,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the transaction, the chief executive officer owned 792,923 shares of the company’s stock, valued at $17,959,705.95. This trade represents a 1.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 281,846 shares of company stock valued at $7,847,619 over the last quarter. Company insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. raised its stake in shares of NewAmsterdam Pharma by 6.8% during the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after purchasing an additional 1,145,128 shares during the period. Capital World Investors grew its holdings in NewAmsterdam Pharma by 1.6% during the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after purchasing an additional 161,289 shares in the last quarter. Maverick Capital Ltd. grew its holdings in NewAmsterdam Pharma by 15.4% during the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after purchasing an additional 292,176 shares in the last quarter. Castle Hook Partners LP purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth $38,062,000. Finally, First Turn Management LLC increased its stake in NewAmsterdam Pharma by 24.6% during the 4th quarter. First Turn Management LLC now owns 893,473 shares of the company’s stock worth $31,343,000 after buying an additional 176,502 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.